{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:50:12Z","timestamp":1790013012348,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["309854"],"award-info":[{"award-number":["309854"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1245\/s10434-022-11916-3","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T11:06:23Z","timestamp":1653563183000},"page":"6660-6668","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Incidence of Occult Breast Cancer in Carriers of BRCA1\/2 or Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy: When is Sentinel Lymph Node Biopsy Indicated?"],"prefix":"10.1245","volume":"29","author":[{"given":"Stephanie M.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Ferroum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Apostolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basmah","family":"Alhassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ipshita","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Basik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Francois","family":"Boileau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarkis","family":"Meterissian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Aleynikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Foulkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"11916_CR1","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/cncr.22176","volume":"107","author":"JC Boughey","year":"2006","unstructured":"Boughey JC, Khakpour N, Meric-Bernstam F, et al. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer. 2006;107:1440\u20137.","journal-title":"Cancer."},{"key":"11916_CR2","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1245\/s10434-017-5925-0","volume":"24","author":"BL Murphy","year":"2017","unstructured":"Murphy BL, Glasgow AE, Keeney GL, Habermann EB, Boughey JC. Selective use of sentinel lymph node surgery in patients undergoing prophylactic mastectomy using intraoperative pathology. Ann Surg Oncol. 2017;24:3032\u20137.","journal-title":"Ann Surg Oncol."},{"key":"11916_CR3","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/jso.23575","volume":"109","author":"PW Bunting","year":"2014","unstructured":"Bunting PW, Cyr AE, Gao F, Margenthaler JA. Sentinel lymph node biopsy during prophylactic mastectomy: is there a role? J Surg Oncol. 2014;109:747\u201350.","journal-title":"J Surg Oncol."},{"key":"11916_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-013-2583-1","volume":"140","author":"DG Evans","year":"2013","unstructured":"Evans DG, Ingham SL, Baildam A, et al. Contralateral mastectomy improves survival in women with BRCA1\/2-associated breast cancer. Breast Cancer Res Treat. 2013;140:135\u201342.","journal-title":"Breast Cancer Res Treat."},{"key":"11916_CR5","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/cncr.11225","volume":"97","author":"ND Kauff","year":"2003","unstructured":"Kauff ND, Brogi E, Scheuer L, et al. Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer. 2003;97:1601\u20138.","journal-title":"Cancer."},{"key":"11916_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1056\/NEJM200107193450301","volume":"345","author":"H Meijers-Heijboer","year":"2001","unstructured":"Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:159\u201364.","journal-title":"N Engl J Med."},{"key":"11916_CR7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/sj.bjc.6602703","volume":"93","author":"TC van Sprundel","year":"2005","unstructured":"van Sprundel TC, Schmidt MK, Rookus MA, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer. 2005;93:287\u201392.","journal-title":"Br J Cancer."},{"key":"11916_CR8","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s10549-018-4953-1","volume":"172","author":"H Yamauchi","year":"2018","unstructured":"Yamauchi H, Okawa M, Yokoyama S, et al. High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound: findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan. Breast Cancer Res Treat. 2018;172:679\u201387.","journal-title":"Breast Cancer Res Treat."},{"key":"11916_CR9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1245\/s10434-014-3883-3","volume":"22","author":"K Yao","year":"2015","unstructured":"Yao K, Liederbach E, Tang R, et al. Nipple-sparing mastectomy in BRCA1\/2 mutation carriers: an interim analysis and review of the literature. Ann Surg Oncol. 2015;22:370\u20136.","journal-title":"Ann Surg Oncol."},{"key":"11916_CR10","doi-asserted-by":"publisher","first-page":"1426369","DOI":"10.1155\/2018\/1426369","volume":"2018","author":"S Camara","year":"2018","unstructured":"Camara S, Pereira D, Andre S, et al. The use of sentinel lymph node biopsy in BRCA1\/2 mutation carriers undergoing prophylactic mastectomy: a retrospective consecutive case-series study. Int J Breast Cancer. 2018;2018:1426369.","journal-title":"Int J Breast Cancer."},{"key":"11916_CR11","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1200\/JCO.19.02859","volume":"38","author":"BG Haffty","year":"2020","unstructured":"Haffty BG, Euhus DM, Pierce LJ. Genetic factors in the locoregional management of breast cancer. J Clin Oncol. 2020;38:2220\u20139.","journal-title":"J Clin Oncol."},{"key":"11916_CR12","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1245\/s10434-016-5268-2","volume":"23","author":"M Pilewskie","year":"2016","unstructured":"Pilewskie M, Stempel M, Rosenfeld H, Eaton A, Van Zee KJ, Morrow M. Do LORIS trial eligibility criteria identify a ductal carcinoma in situ patient population at low risk of upgrade to invasive carcinoma? Ann Surg Oncol. 2016;23:3487\u201393.","journal-title":"Ann Surg Oncol."},{"key":"11916_CR13","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1245\/s10434-017-6018-9","volume":"24","author":"LJ Grimm","year":"2017","unstructured":"Grimm LJ, Ryser MD, Partridge AH, et al. Surgical upstaging rates for vacuum-assisted biopsy proven DCIS: implications for active surveillance trials. Ann Surg Oncol. 2017;24:3534\u201340.","journal-title":"Ann Surg Oncol."},{"key":"11916_CR14","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ejso.2016.01.020","volume":"42","author":"O Gentilini","year":"2016","unstructured":"Gentilini O, Botteri E, Dadda P, et al. Physical function of the upper limb after breast cancer surgery. results from the SOUND (Sentinel Node vs Observation After Axillary Ultra-souND) trial. Eur J Surg Oncol. 2016;42:685\u20139.","journal-title":"Eur J Surg Oncol."},{"key":"11916_CR15","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","volume":"22","author":"TR Rebbeck","year":"2004","unstructured":"Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22:1055\u201362.","journal-title":"J Clin Oncol."},{"key":"11916_CR16","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1245\/s10434-007-9449-x","volume":"14","author":"BA Heemskerk-Gerritsen","year":"2007","unstructured":"Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, et al. Prophylactic mastectomy in BRCA1\/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol. 2007;14:3335\u201344.","journal-title":"Ann Surg Oncol."},{"key":"11916_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1245\/s10434-013-3230-0","volume":"21","author":"AW Peled","year":"2014","unstructured":"Peled AW, Irwin CS, Hwang ES, Ewing CA, Alvarado M, Esserman LJ. Total skin-sparing mastectomy in BRCA mutation carriers. Ann Surg Oncol. 2014;21:37\u201341.","journal-title":"Ann Surg Oncol."},{"key":"11916_CR18","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/cncr.23298","volume":"112","author":"SA McLaughlin","year":"2008","unstructured":"McLaughlin SA, Stempel M, Morris EA, Liberman L, King TA. Can magnetic resonance imaging be used to select patients for sentinel lymph node biopsy in prophylactic mastectomy? Cancer. 2008;112:1214\u201321.","journal-title":"Cancer."},{"key":"11916_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2214\/AJR.21.26561","volume":"218","author":"AS Taliaferro","year":"2022","unstructured":"Taliaferro AS, Price ER, Hayward JH, et al. Utility and outcomes of preoperative screening breast MRI for planned bilateral prophylactic mastectomy in high-risk patients. AJR Am J Roentgenol. 2022;218:241\u20138.","journal-title":"AJR Am J Roentgenol."},{"key":"11916_CR20","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/S1470-2045(20)30472-1","volume":"21","author":"PM Poortmans","year":"2020","unstructured":"Poortmans PM, Weltens C, Fortpied C, et al. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922\/10925): 15-year results of a randomised, phase 3 trial. Lancet Oncol. 2020;21:1602\u201310.","journal-title":"Lancet Oncol."},{"key":"11916_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1415340","volume":"373","author":"TJ Whelan","year":"2015","unstructured":"Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373:307\u201316.","journal-title":"N Engl J Med."},{"key":"11916_CR22","doi-asserted-by":"crossref","unstructured":"de Gregorio A, Janni W, Friedl TWP, et al. The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer: a pooled analysis of the randomised clinical trials PlanB and SUCCESS C. Br J Cancer. 2022.","DOI":"10.1038\/s41416-021-01690-6"},{"key":"11916_CR23","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394\u2013405.","journal-title":"N Engl J Med."},{"key":"11916_CR24","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/bjs.11110","volume":"106","author":"A Karakatsanis","year":"2019","unstructured":"Karakatsanis A, Hersi AF, Pistiolis L, et al. Effect of preoperative injection of superparamagnetic iron oxide particles on rates of sentinel lymph node dissection in women undergoing surgery for ductal carcinoma in situ (SentiNot study). Br J Surg. 2019;106:720\u20138.","journal-title":"Br J Surg."},{"key":"11916_CR25","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jamcollsurg.2008.06.139","volume":"207","author":"A Karam","year":"2008","unstructured":"Karam A, Stempel M, Cody HS III, Port ER. Reoperative sentinel lymph node biopsy after previous mastectomy. J Am Coll Surg. 2008;207:543\u20138.","journal-title":"J Am Coll Surg."},{"key":"11916_CR26","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1245\/s10434-021-10986-z","volume":"29","author":"E Vicini","year":"2022","unstructured":"Vicini E, Leonardi MC, Fontana SKR, et al. How to perform repeat sentinel node biopsy safely after a previous mastectomy: technical features and oncologic outcomes. Ann Surg Oncol. 2022;29:1750\u201360.","journal-title":"Ann Surg Oncol."},{"issue":"Suppl 3","key":"11916_CR27","doi-asserted-by":"publisher","first-page":"S529","DOI":"10.1245\/s10434-015-4787-6","volume":"22","author":"G Vugts","year":"2015","unstructured":"Vugts G, Maaskant-Braat AJ, Voogd AC, et al. Improving the success rate of repeat sentinel node biopsy in recurrent breast cancer. Ann Surg Oncol. 2015;22(Suppl 3):S529\u201335.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-11916-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-11916-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-11916-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T11:13:06Z","timestamp":1663758786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-11916-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["11916"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-11916-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]},"assertion":[{"value":"4 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jean-Francois Boileau reports honoraria from Roche, Novartis, Genomic Health, Pfizer, Allergan, and Merck; personal fees from Roche, Genomic Health, NanoString Technologies, Pfizer, Eli Lilly, Novartis, and Merck; and travel support from Roche, GlaxoSmithKline, Novartis, Pfizer, and Lifecell outside the submitted work. The remaining authors have no conflicts of interest.Jean-Francois Boileau reports honoraria from Roche, Novartis, Genomic Health, Pfizer, Allergan, and Merck; personal fees from Roche, Genomic Health, NanoString Technologies, Pfizer, Eli Lilly, Novartis, and Merck; and travel support from Roche, GlaxoSmithKline, Novartis, Pfizer, and Lifecell outside the submitted work. The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}